Get the Stockscreener App
2.06
6.74%
0.13
Tiziana Life Sciences Ltd stock is traded at $2.06, with a volume of 337.31K.
It is up +6.74% in the last 24 hours and up +27.16% over the past month.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
See More
Previous Close:
$1.93
Open:
$1.92
24h Volume:
337.31K
Relative Volume:
1.04
Market Cap:
$240.71M
Revenue:
-
Net Income/Loss:
$-13.73M
P/E Ratio:
-15.85
EPS:
-0.13
Net Cash Flow:
$-3.92M
1W Performance:
+4.57%
1M Performance:
+27.16%
6M Performance:
+151.25%
1Y Performance:
+64.80%
1-Day Range:
$1.906
$2.07
1-Week Range:
$1.7256
$2.07
52-Week Range:
$0.6295
$2.60
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Name
Tiziana Life Sciences Ltd
Sector
Industry
Phone
-
Address
-
Compare TLSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
2.06 | 220.84M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Dec-17-18 | Initiated | Laidlaw | Buy |
Tiziana Life Sciences Ltd Stock (TLSA) Latest News
Trendlines Suggest Tiziana Life Sciences Ltd May Bottom Out SoonJuly 2025 Gainers & High Accuracy Trade Alerts - thegnnews.com
Price Reversal in Tiziana Life Sciences Ltd Traders Watch CloselyEarnings Performance Report & AI Driven Stock Reports - 선데이타임즈
We Think Tiziana Life Sciences (NASDAQ:TLSA) Can Easily Afford To Drive Business Growth - 富途牛牛
Is Tiziana Life Sciences Ltd stock bottoming outMarket Movement Recap & Risk Controlled Stock Alerts - Newser
Using economic indicators to assess Tiziana Life Sciences Ltd potentialJuly 2025 Institutional & Expert Approved Trade Ideas - Newser
What institutional flow reveals about Tiziana Life Sciences Ltd2025 Pullback Review & Free Growth Oriented Trading Recommendations - Newser
Tiziana Life Sciences Ltd Inches Toward Key Resistance — Will It BreakWeekly Market Outlook & Weekly Sector Rotation Insights - 선데이타임즈
Multi factor analysis applied to Tiziana Life Sciences LtdJuly 2025 Snapshot & Smart Allocation Stock Tips - Newser
Analyzing Tiziana Life Sciences Ltd with multi timeframe chartsPortfolio Risk Report & Fast Exit Strategy with Risk Control - Newser
Can Tiziana Life Sciences Ltd hit a new high this monthMarket Performance Summary & Real-Time Stock Entry Alerts - Newser
Why Tiziana Life Sciences Ltd stock attracts strong analyst attentionMarket Weekly Review & Reliable Volume Spike Trade Alerts - Newser
Is Tiziana Life Sciences Ltd in a bullish channel2025 Price Targets & Long-Term Growth Plans - thegnnews.com
Can Traders Expect Breakout From Tiziana Life Sciences Ltd This WeekQuarterly Profit Review & Reliable Entry Point Alerts - metal.it
Smart tools for monitoring Tiziana Life Sciences Ltd’s price actionJuly 2025 Catalysts & Free Safe Entry Trade Signal Reports - Newser
Should you hold or exit Tiziana Life Sciences Ltd nowJuly 2025 Breakouts & Weekly Watchlist of Top Performers - Newser
Tiziana Life Sciences Ltd stock momentum explainedWeekly Investment Report & Verified Stock Trade Ideas - Newser
Tiziana Life Sciences doses first MSA patient in new trial – ICYMI - Proactive financial news
Screener Results Flag Tiziana Life Sciences Ltd as Oversold2025 Risk Factors & Weekly Breakout Opportunity Watchlist - kangso.co.kr
Will Tiziana Life Sciences Ltd stock benefit from interest rate changesPortfolio Value Summary & High Yield Stock Recommendations - Newser
Applying sector rotation models to Tiziana Life Sciences LtdM&A Rumor & AI Driven Price Forecasts - Newser
Tiziana Life Sciences shares rise 2% premarket after dosing first patient in Phase 2a trial for MSA. - AInvest
Tiziana Life Sciences doses first patient in Phase 2a trial of Foralumab for rare disease - Proactive financial news
RSI Suggests Rebound May Be Near in Tiziana Life Sciences LtdWatch List & Precise Swing Trade Entry Alerts - newsimpact.co.kr
Tiziana Life Sciences doses first patient in Phase 2a MSA trial - Proactive financial news
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy - The Manila Times
Novel Intranasal Treatment Begins Trial for Incurable Brain Disorder Affecting 50,000 Americans - Stock Titan
What makes Tiziana Life Sciences Ltd stock price move sharplyJuly 2025 Setups & Expert Verified Stock Movement Alerts - Newser
Top chart patterns to watch in Tiziana Life Sciences LtdBuy/Sell Zone Confirmation Technical Analysis - Newser
What moving averages say about Tiziana Life Sciences Ltd [Trade Analysis Report]Free Real-Time Buy Signal Notifications - Newser
Tiziana Life Sciences Ltd (TLSA) Stock: A Year of Decreases and Increases - investchronicle.com
Has Tiziana Life Sciences Ltd formed a bullish divergenceEquity Market Return Forecast Model Update - Newser
Tiziana Life’s Phase IIa multiple system atrophy study gets FDA approval - Yahoo Finance
How to interpret RSI for Tiziana Life Sciences Ltd stockPredictable Return Plan with Entry Guidance - Newser
What high frequency data says about ENDRA Life Sciences Inc.Entry and Exit Strategy for Swing Traders - Newser
What analysts say about Tiziana Life Sciences Ltd stock outlookDaily Technical Forecast for Quick Gains - Newser
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy - Informazione.it
Proactive financial news: fast, accessible, and actionable articles and videos for the global investment audience. - Proactive financial news
Market movers: Micron, Barrick, Tiziana Life Sciences, American Resources... - Proactive financial news
What moving averages say about Tiziana Life Sciences LtdSteady Return Plan Based on Data Analysis - Newser
Tiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDA - Proactive financial news
Tiziana to begin testing foralumab in multiple system atrophy - Seeking Alpha
Tiziana Life Sciences Ltd Stock (TLSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):